Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy
A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy
Nonsmall Cell Lung Cancer|Squamous Cell Carcinoma of the Head and Neck
DRUG: Nolbaxol|DRUG: Taxotere|DRUG: cisplatin
Progression-Free Survival (PFS), Every 8 weeks after post-dosing follow-up visit, and conducted until disease progression or up to 11 months.
Overall Response Rate (ORR), Every 8 weeks after post-dosing follow-up visit, and conducted until disease progression or up to 11 months.|Adverse Events as a measure on safety, Adverse event will be evaluated during the study regimens treatment period and up to 8 weeks after the last dose of study regimen visit.
A Post-marketing Surveillance Study to Evaluate the Effectiveness and Safety of Docetaxel-Based Chemotherapy